DARPA awarded Battelle, NxStage Medical and Aethlon Medical a contract to develop a device to treat sepsis, which can arise from as much as 10 percent of combat wounds, for military use, according to a Battelle press release. The contract, which could lead to $22.8 million dollars and four years worth of work for the […]
...we ask ourselves whether the small emerging med-tech company can achieve success (and funding) with a “tons cheaper” value proposition. In theory, any company starting fresh with design and manufacturing should be able to take advantage of Moore’s law in a way that the big guys with vast installed bases and capital investments can’t. The opportunity for success is there, but not every company or technology is cut out to win at price-cutting.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
NxStage Medical Inc. (NASDAQ:NXTM) will not renew one of its key supplier agreements for the blood tubing sets used in its System One home dialysis machines when it expires next January. The Lawrence, Mass.-based renal products maker said that it will let a deal with Kawasumi Laboratories Inc. expire Jan. 31, 2012. The Japanese company […]
NxStage Medical Inc. (NASDAQ:NXTM) handed out pay raises to several members of its leadership team after a year that saw the dialysis maker boost sales 20 percent and cut its net losses. The Lawrence, Mass.-based company rewarded CEO Jeffrey Burbank for a job well done with a 20 percent bump in his base salary, bringing […]
NxStage Medical Inc. (NASDAQ:NXTM) grossed $66.1 million from the sale of 3.2 million shares of its common stock. The Lawrence, Massachusetts-based home hemodialysis products maker sold the shares for $20.65 each, according to a filing with the federal Securities & Exchange Commission. NXTM shares, which closed at $21.38 yesterday, were trading at $20.67 in early-afternoon […]